Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
Large granular lymphocyte (LGL) leukemia is characterized by the expansion of antigen-activated cytotoxic T lymphocytes. These leukemic cells are resistant to Fas-mediated apoptosis despite expressing high levels of Fas. We found that leukemic LGL from 19 patients displayed high levels of activated STAT3. Treatment of leukemic LGL with the JAK-selective tyrosine kinase inhibitor AG-490 induced apoptosis with a corresponding decrease in STAT-DNA binding activity. Moreover, using an antisense oligonucleotide approach to diminish STAT3 expression, we found that Fas sensitivity was restored in leukemic LGL. AG-490-induced apoptosis in leukemic LGL was independent of Bcl-xL or Bcl-2 expression. However, we found that the Bcl-2-family protein Mcl-1 was significantly reduced by AG-490 treatment. Activated STAT3 was shown to bind an SIE-related element in the murine mcl-1 promoter. Using a luciferase reporter assay, we demonstrated that v-src overexpression in NIH3T3 induced STAT3-dependent transcriptional activity from the mcl-1 promoter and increased endogenous Mcl-1 protein levels. We conclude that STAT3 activation contributed to accumulation of the leukemic LGL clones. These findings suggest that investigation should focus on novel strategies targeting STAT3 in the treatment of LGL leukemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Other inhibition strategies include the introduction of antisense oligonucleotides, as in the case of the Isis Pharmaceuticals, Inc/AstraZeneca drug in clinical development, designed to cause degradation of STAT3 mRNA or prevent its translation via complementary base pairing, thereby reducing total STAT3 protein levels.105”
From Critical analysis of the potential for targeting STAT3 in human malignancy (2013) · cites this paper as [105]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“the STAT3 protein in the peripheral blood mononuclear cell extracts isolated from patients with large granular lymphocyte leukemia has been reported to bind to the murine SIE motif (9).”
The cited source says what the claim attributes to it.
In the citing paper
“IL-6 plays a significant role in inducing tumor growth as it interacts with the receptor, JAK, to induce STAT-3 activation. STAT-3 then activates oncogenes such as MCL-1 (29) and upregulates genes involved in proliferation such as Cyclin-D1 (30). These activities result in the induction of cancer cell proliferation.”
From Tumor-Induced Inflammatory Cytokines and the Emerging Diagnostic Devices for Cancer Detection and Prognosis (2021) · cites this paper as [29]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis
Nicholson, D. W., Ali, A., Thornberry, N. A., Vaillancourt, J. P., Ding, C. K., Gallant, M., Gareau, Y., Griffin, P. R., Labelle, M., Lazebnik, Y. A., et al. (1995) · Nature · doi:10.1038/376037a0 · Cited by 3,979 · cited 2×
“Proteolytic cleavage and activation of a cascade of caspases (death proteases) mediate the cleavage of cellular targets, resulting in programmed cell death (38, 39).”
BackgroundLymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis
Watanabe-Fukunaga, R., Brannan, C. I., Copeland, N. G., Jenkins, N. A., & Nagata, S. (1992) · Nature · doi:10.1038/356314a0 · Cited by 2,885 · cited 1×
“Animal models of lymphoproliferative disorders with autoimmune features such as lpr/lpr and gld/gld mice are characterized by insensitivity to Fasdependent cell death due to mutations in the FasR or FasL, respectively (6, 7).”
BackgroundBromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., & Darnell, J. E. (1999) · Cell · doi:10.1016/s0092-8674(00)81959-5 · Cited by 2,790
Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway
HEINRICH, P. C., BEHRMANN, I., MÜLLER-NEWEN, G., SCHAPER, F., & GRAEVE, L. (1998) · Biochemical Journal · doi:10.1042/bj3340297 · Cited by 2,130
Catlett-Falcone, R., Landowski, T. H., Oshiro, M. M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernández-Luna, J. L., Nuñez, G., et al. (1999) · Immunity · doi:10.1016/s1074-7613(00)80011-4 · Cited by 1,638
Self-citationGeneralized lymphoproliferative disease in mice, caused by a point mutation in the fas ligand
Takahashi, T., Tanaka, M., Brannan, C. I., Jenkins, N. A., Copeland, N. G., Suda, T., & Nagata, S. (1994) · Cell · doi:10.1016/0092-8674(94)90375-1 · Cited by 1,528 · cited 1×
“Animal models of lymphoproliferative disorders with autoimmune features such as lpr/lpr and gld/gld mice are characterized by insensitivity to Fasdependent cell death due to mutations in the FasR or FasL, respectively (6, 7).”
BackgroundMCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2.
Kozopas, K. M., Yang, T., Buchan, H. L., Zhou, P., & Craig, R. W. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3516 · Cited by 961
Enhanced DNA-Binding Activity of a Stat3-Related Protein in Cells Transformed by the Src Oncoprotein
Yu, C.-L., Meyer, D. J., Campbell, G. S., Larner, A. C., Carter-Su, C., Schwartz, J., & Jove, R. (1995) · Science · doi:10.1126/science.7541555 · Cited by 931 · cited 11×
“Transfection of the indicated plasmids into NIH3T3 cells was performed using CaP04, as described previously (28). pM-v-src and pSG5-STAT3β are plasmid vectors expressing v-src and a dominant negative mutant of STAT3, respectively.”
MethodInfluentialSelf-citationInhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor
Meydan, N., Grunberger, T., Dadi, H., Shahar, M., Arpaia, E., Lapidot, Z., Leeder, J. S., Freedman, M., Cohen, A., Gazit, A., et al. (1996) · Nature · doi:10.1038/379645a0 · Cited by 897 · cited 2×
“Therefore, we used a tyrphostin inhibitor (AG-490) selective for the JAKfamily tyrosine kinases to determine whether inhibition of the pathway upstream of STAT activation would affect apoptosis in LGL leukemia cells (32).”
MethodWakao, H., Gouilleux, F., & Groner, B. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06495.x · Cited by 826 · cited 2×
“The degree of binding was determined by electrophoretic analysis on a 5% native polyacrylamide gel as described previously (19, 31).”
BackgroundMethod
Cited by
Items 301–400 of 643
Vitamin D decreases STAT phosphorylation and inflammatory cytokine output in T-LGL leukemia
Olson, K. C., Larkin, P. M. K., Olson, T. L., Tan, S., Rainbow, R. J., Feith, D. J., & Loughran, T. P. (2016) · Cancer Biology & Therapy · doi:10.1080/15384047.2016.1235669 · Cited by 38
“This indicates vitamin D supplementation could be a viable therapeutic option for T-LGLL.”
BackgroundSelf-citationImmunologic effects on the haematopoietic stem cell in marrow failure
Patel, B. A., Giudice, V., & Young, N. S. (2021) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2021.101276 · Cited by 41
Large Granular Lymphocyte Leukemia: From Dysregulated Pathways to Therapeutic Targets
LeBlanc, F., Zhang, D., Liu, X., & Loughran, T. P. (2012) · Future Oncology · doi:10.2217/fon.12.75 · Cited by 44
“STAT3 has been found to be constitutively activated in patients with leukemic LGLs [9].”
BackgroundInfluentialSelf-citationPaiva, C. J., Rowland, T., Sreekantham, B., Godbersen, C., Best, S., Kaur, P., Loriaux, M., Spurgeon, S. E. F., Danilova, O. V., & Danilov, A. V. (2017) · Haematologica · doi:10.3324/haematol.2017.170571 · Cited by 38
“BAFF triggered robust activation of the noncanonical and, to a lesser extent, canonical NFκB, leading to distinctive expression of Bcl-2 family proteins, predominantly Mcl-1.”
BackgroundInfluentialTrécul, A., Morceau, F., Dicato, M. A., & Diederich, M. F. (2012) · Genes & Nutrition · doi:10.1007/s12263-012-0281-y · Cited by 36
Watters, R. J., Fox, T. E., Tan, S., Shanmugavelandy, S. S., Choby, J. E., Broeg, K., Liao, J., KESTER, M. A., Cabot, M. C., Loughran, T. P., et al. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.752485 · Cited by 36
Self-citationDiallo, M., & Herrera, F. (2021) · FEBS Journal · doi:10.1111/febs.16116 · Cited by 38
Mesa, R. A., Tefferi, A., Lasho, T., Loegering, D. A., McClure, R. F., Powell, H. L., Dai, N. T., Steensma, D. P., & Kaufmann, S. H. (2006) · Leukemia · doi:10.1038/sj.leu.2404338 · Cited by 38
Kim, D. J., Kataoka, K., Sano, S., Connolly, K., Kiguchi, K., & DiGiovanni, J. (2009) · Molecular Carcinogenesis · doi:10.1002/mc.20527 · Cited by 36
Giri, J., Srivastav, S., Basu, M., Palit, S., Gupta, P., & Ukil, A. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.672873 · Cited by 38
“Previous reports suggested that CREB, activated via the PI3K/AKT pathway and STAT3, activated via the JAK/STAT pathway, are the two major transcriptional regulators of MCL-1 (51, 52).”
BackgroundCoppe, A., Andersson, E. I., Binatti, A., Gasparini, V. R., Bortoluzzi, S., Clemente, M. J., Herling, M., Maciejewski, J. P., Mustjoki, S. M., & Bortoluzzi, S. (2017) · Leukemia · doi:10.1038/leu.2017.49 · Cited by 36
“The network of genes mutated in individual CD8+ and CD4+ or NK LGL leukemia patients and in each patient subgroup are presented in the Supplementary Figures 7-9.”
A novel mechanism of methylglyoxal cytotoxicity in neuroglial cells
Lee, H. K., Seo, I. A., Suh, D. J., Lee, H., & Park, H. T. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05764.x · Cited by 44
Contribution of STAT3 to the activation of survivin by GM-CSF in CD34+ cell lines
Gu, L., Chiang, K., Zhu, N., Findley, H. W., & Zhou, M. (2007) · Experimental Hematology · doi:10.1016/j.exphem.2007.03.007 · Cited by 37
Yabe, M., Medeiros, L. J., Wang, S. A., Konoplev, S. N., Ok, C. Y., Loghavi, S., Lu, G. G., Flores, L. B., Khoury, J. D., Cason, R. C., et al. (2015) · American Journal of Clinical Pathology · doi:10.1309/ajcpjsa1e1ywszey · Cited by 35
“0) Hemoglobin ≤10 g/dL 3 (21) Platelets, median (range), × 109/L 145 (10-295) Platelets ≤150 × 109/L 7 (50) Platelets ≤100 × 109/L 4 (29) Platelets ≤20 × 109/L 3 (21) Therapy, No.”
BackgroundMS‐1020 is a novel small molecule that selectively inhibits JAK3 activity
Kim, B., Oh, S., Yin, C., Lee, S., Kim, E., Kim, M., Sandoval, C., Jayabose, S., Bach, E. A., Lee, H., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07925.x · Cited by 35
“…downregulates the expression of anti-apoptotic genes and induces apoptosis Aberrant JAK/STAT signalling is thought to upregulate the expression of anti-apoptotic genes and thus enable cancer cells to escape cancer treatment (Epling-Burnette et al, 2001; Mahboubi et al, 2001; Battle & Frank, 2002).”
BackgroundAssi, H. H., Paran, C., VanderVeen, N. T., Savakus, J. C., Doherty, R., Petruzzella, E., Hoeschele, J. D., Appelman, H. D., Raptis, L. H., Mikkelsen, T., et al. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.214619 · Cited by 35
“STAT3 is also known to mediate the transcription of genes that regulate apoptosis (Epling-Burnette et al., 2001; Gritsko et al., 2006).”
BackgroundPancreatic STAT3 Protects Mice against Caerulein-Induced Pancreatitis via PAP1 Induction
Shigekawa, M., Hikita, H., Kodama, T., Shimizu, S., Li, W., Uemura, A., Miyagi, T., Hosui, A., Kanto, T., Hiramatsu, N., et al. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.08.038 · Cited by 37
MACC1 regulates Fas mediated apoptosis through STAT1/3 – Mcl-1 signaling in solid cancers
Radhakrishnan, H., Ilm, K., Walther, W., Shirasawa, S., Sasazuki, T., Daniel, P. T., Gillissen, B. F., & Stein, U. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.06.020 · Cited by 35
Marchand, T., Lamy, T., & Loughran, T. P. (2024) · Blood · doi:10.1182/blood.2023021790 · Cited by 47
Self-citationSuppressor of cytokine signaling 3 expression in anaplastic large cell lymphoma
Cho‐Vega, J. H., Rassidakis, G. Z., Amin, H. M., Tsioli, P., Spurgers, K. B., Remache, Y. K., Vega, F., Goy, A. H., Gilles, F., & Medeiros, L. J. (2004) · Leukemia · doi:10.1038/sj.leu.2403495 · Cited by 33
Yamamoto, K., Mizumoto, A., Nishimura, K., Uda, A., Mukai, A., Yamashita, K., Kume, M., Makimoto, H., Bito, T., Nishigori, C., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102110 · Cited by 34
“STAT3 regulates the expression of Bcl-2, Mcl-1, and survivin, which are apoptosis suppressors [12,13,28].”
BackgroundObesity Promotes Liver Carcinogenesis via Mcl-1 Stabilization Independent of IL-6Rα Signaling
Gruber, S., Straub, B. K., Ackermann, P. J., Wunderlich, C. M., Mauer, J., Seeger, J. M., Büning, H., Heukamp, L., Kashkar, H., Schirmacher, P., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.07.023 · Cited by 32
“While Mcl-1 expression at the transcriptional level depends on PI3K-mediated signal transduction as well as IL-6evoked signaling (Epling-Burnette et al., 2001; Jourdan et al., 2003; Wang et al., 1999), the dynamic turnover rate of Mcl-1 is controlled by GSK-3b phosphorylation leading to its…”
BackgroundTaking the Myc is bad for Theileria
Dessauge, F., Lizundia, R., Baumgartner, M., Chaussepied, M., & Langsley, G. (2005) · Trends in Parasitology · doi:10.1016/j.pt.2005.06.003 · Cited by 34
Balakrishnan, K., Burger, J. A., Fu, M., Doifode, T., Wierda, W. G., & Gandhi, V. V. (2014) · Neoplasia · doi:10.1016/j.neo.2014.10.002 · Cited by 36
“Activated STAT3 is shown to bind in SIE related element in the murine Mcl-1 promoter and increase Mcl-1 protein levels [16].”
BackgroundSTAT3β is a tumor suppressor in acute myeloid leukemia
Aigner, P., Mizutani, T., Horvath, J., Eder, T., Heber, S., Lind, K., Just, V., Moll, H. P., Yeroslaviz, A., Fischer, M. J. M., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018026385 · Cited by 35
Intersection Between Large Granular Lymphocyte Leukemia and Rheumatoid Arthritis
Moosic, K. B., Ananth, K., Andrade, F., Feith, D. J., Darrah, E., & Loughran, T. P. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.869205 · Cited by 32
Self-citationActivation Status of the JAK/STAT3 Pathway in Mantle Cell Lymphoma
Yared, M. A., Khoury, J. D., Medeiros, L. J., Rassidakis, G. Z., & Lai, R. L. (2005) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2005-129-990-asotsp · Cited by 33
T-large granular lymphocyte leukemia: current molecular concepts
Włodarski, M. W., Schade, A. E., & Maciejewski, J. P. (2006) · Hematology · doi:10.1080/10245330600774793 · Cited by 32
“STAT3 was shown to be involved in cellular transformation along with an active Src family kinase [74] and appears to be constitutively activated in T-LGL cells [75,76].”
BackgroundPotential Role for STAT3 Inhibitors in Glioblastoma
Jackson, C. M., Ruzevick, J., Amin, A. G., & Lim, M. K. (2012) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2012.04.002 · Cited by 32
Myeloid cell leukemia-1 as a therapeutic target
Mandelin, A. M., & Pope, R. M. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.3.363 · Cited by 36
Ma, L., Zhu, Z., Jiang, L., Sun, X. Y., Lu, X., Zhou, M., Qian, S., & Li, J. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1007507 · Cited by 33
Włodarski, M. W., Nearman, Z. P., Jankowska, A. M., Babel, N., Powers, J., Leahy, P. S., Volk, H., & Maciejewski, J. P. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0107073 · Cited by 31
“transducer): 12/3 IL-10: 12/3 IL-8: 12/3 Western blot [39] Constitutive expression of STAT3 STAT3 13/3”
LeBlanc, F., Liu, X., Hengst, J. A., Fox, T. E., Calvert, V. S., Petricoin, E. F., Yun, J. K., Feith, D. J., & Loughran, T. P. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1078949 · Cited by 33
“The JAK/STAT pathway is dysregulated in both T- and NK-LGL leukemia.(5,39) The RPMA targeting of JAK/STAT signaling was verified by immunoblotting analysis and illustrates that PSTAT3, P-STAT5, P-JAK1 and P-JAK2 decrease dose-dependently with SKI-178 treatment (Fig.”
BackgroundSelf-citationKuusanmäki, H. A., Dufva, O., Parri, E., van Adrichem, A. J., Rajala, H. L. M., Majumder, M. M., Yadav, B., Parsons, A., Chan, W. C., Wennerberg, K., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22178 · Cited by 31
“In lymphoproliferative malignancies, JAK/STAT3 signaling is commonly deregulated and thus an attractive target for treatment [3-6].”
BackgroundAntiapoptotic Signaling Pathways in Non–Small-Cell Lung Cancer: Biology and Therapeutic Strategies
Haura, E. B., Cress, W. D., Chellappan, S., Zheng, Z., & Bepler, G. (2004) · Clinical Lung Cancer · doi:10.3816/clc.2004.n.025 · Cited by 33
Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms
Atallah, E. L., & Verstovšek, S. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.14 · Cited by 31
Subclonal STAT3 mutations solidify clonal dominance
Kerr, C. M., Clemente, M. J., Chomczynski, P., Przychodzen, B. P., Nagata, Y., Ademà, V., Visconte, V., Lichtin, A. E., Mustjoki, S. M., Radivoyevitch, T., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018027862 · Cited by 30
“Vb CDR3 sequences acting as biological bar codes can be used to identify and quantify these expansions and to diagnose LGL.(11-17) Deep TCR repertoire sequencing can precisely identify and assess CDR3 diversity and quantify immunodominant expansions.”
BackgroundLeBlanc, F., Pearson, J. M., Tan, S., Cheon, H., Xing, J. C., Dunton, W., Feith, D. J., & Loughran, T. P. (2020) · British Journal of Haematology · doi:10.1111/bjh.16530 · Cited by 34
Self-citationA novel small molecule Met inhibitor, PF2362376, exhibits biological activity against osteosarcoma
Liao, A. T., McCleese, J., Kamerling, S. G., Christensen, J. G., & London, C. A. (2007) · Veterinary and Comparative Oncology · doi:10.1111/j.1476-5829.2007.00137.x · Cited by 35
PPARδ Is a Type 1 IFN Target Gene and Inhibits Apoptosis in T Cells
Al‐Yacoub, N., Romanowska, M., Krauß, S., Schweiger, S., & Foerster, J. (2008) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.32 · Cited by 36
“In human T-cell leukemia cells, STAT3 phosphorylation blocks apoptosis by transcriptional induction of the bcl-2 member Mcl-1 (Epling-Burnette et al., 2001).”
BackgroundReactive Oxygen Species and Oncoprotein Signaling-A Dangerous Liaison
Chong, S. J. F., Lai, J. X. H., Eu, J. Q., Bellot, G. L., & Pervaiz, S. (2018) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7441 · Cited by 30
“In addition, the sustained activation of STAT3 could also enhance the expression of other antiapoptotic proteins such as Bcl-xL and Mcl-1 (31, 84, 200).”
Chronic neutropenia in LGL leukemia and rheumatoid arthritis
Gazitt, T., & Loughran, T. P. (2017) · Hematology · doi:10.1182/asheducation-2017.1.181 · Cited by 35
“Constitutive STAT3 activation in all T-LGLL patients was discovered quite some time ago.(17) Because an activating mutation is only present in less than half of these patients, the mechanism of activation in these other patients remains uncertain.”
BackgroundSelf-citationWu, B., Fathi, S., Mortley, S., Mohiuddin, M., Jang, Y. C., & Oyelere, A. K. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115345 · Cited by 31
Activity of the Suppressor of Cytokine Signaling–3 Promoter in Human Non–Small-Cell Lung Cancer
He, B., You, L., Xu, Z., Mazières, J., Lee, A. Y., & Jablons, D. M. (2004) · Clinical Lung Cancer · doi:10.3816/clc.2004.n.015 · Cited by 31
Zhou, J., Ning, Z., Wang, B., Yun, E.-J., Zhang, T., Pong, R. C., Fazli, L., Gleave, M. E., Zeng, J., Fan, J., et al. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.289 · Cited by 31
Lee, J. C., Ahn, K. S., Jeong, S., Jung, J. H., Kwon, T., Rhee, Y., Kim, S., Kim, S., Yoon, H., Zhu, S., et al. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23077 · Cited by 29
“GENIPIN SUPPRESSES THE STAT3 TARGET GENES STAT3 has been known to be able to regulate the genes involved in cell proliferation, survival, and angiogenesis [Bromberg et al., 1999; Epling-Burnette et al., 2001; Yu and Jove, 2004; Aggarwal et al., 2006].”
BackgroundCD95 Antigen Mutations in Hematopoietic Malignancies
Landowski, T. H., Moscinski, L. C., Burke, R., Buyuksal, I., Painter, J. S., Goldstein, S., & Dalton, W. S. (2001) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190109097702 · Cited by 32
Tian, K., Liu, W., Zhang, J., Fan, X., Liu, J., Zhao, N., Yao, C., & Miao, G. (2020) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-020-00207-y · Cited by 29
Self-citationSong, M., Wang, C., Yang, H., Chen, Y., Feng, X., Li, B., & Fan, H. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00680 · Cited by 32
Tu, M., He, L., You, Y., Li, J., Yao, N., Qu, C., Huang, W., Xu, L., Luo, R., & Hong, J. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03040-5 · Cited by 30
Yao, R., Chen, Y., Hao, H., Guo, Z., Cheng, X., Ma, Y., Ji, Q., Yang, X., Wang, Y., Li, X., et al. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00677-9 · Cited by 31
Li, H., Xiao, W., Ma, J., Zhang, Y., Li, R., Ye, J., Wang, X., Zhong, X., & Wang, S. (2014) · Europe PMC (PubMed Central) · Cited by 31
Olson, K. C., Larkin, P. M. K., Signorelli, R., Hamele, C. E., Olson, T. L., Conaway, M. R., Feith, D. J., & Loughran, T. P. (2018) · Cytokine · doi:10.1016/j.cyto.2018.09.016 · Cited by 28
Self-citationYu, Z., Huang, R., Xiao, H., Sun, W., Shan, Y., Wang, B., Zhao, T., Dong, B., Zhao, Z., Liu, X., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25169 · Cited by 29
Yang, Y., Ikezoe, T., Zheng, Z., Taguchi, H., Koeffler, H., & Zhu, W. (2007) · International Journal of Oncology · doi:10.3892/ijo.31.3.593 · Cited by 33
The role of constitutively activated STAT3 in B16 melanoma cells
Pfeffer, L. M., Yang, C. H., Fan, M., & Yue, J. (2010) · International Journal of Interferon Cytokine and Mediator Research · doi:10.2147/ijicmr.s6657 · Cited by 34
“Inhibition of constitutive STAT3 activation in diverse tumor cell lines, by blocking of tyrosine kinase signaling using small molecular inhibitors, has been repeatedly associated with growth suppression and induction of cell death.(12,13) In contrast, normal cells or tumor cells lacking STAT activation are typically m…”
BackgroundThe Effects of Resveratrol on Prostate Cancer through Targeting the Tumor Microenvironment
Silk, N., Reich, J. S., Sinha, R., Chawla, S., Geary, K. R., & Zhang, D. (2021) · Journal of Xenobiotics · doi:10.3390/jox11010002 · Cited by 28
“The authors posit that apoptosis is triggered by downregulating downstream factors like Bcl-x, Mcl-, and Cyclin D1 [67,68].”
BackgroundStat3 Expression and Its Correlation with Proliferation and Apoptosis/Autophagy in Gliomas
Caldera, V., Mellai, M., Annovazzi, L., Valente, G., Tessitore, L., & Schiffer, D. (2008) · Journal of Oncology · doi:10.1155/2008/219241 · Cited by 28
Papanikolaou, V., Stefanou, N., Dubos, S., Papathanasiou, I. V., Palianopoulou, M., Valiakou, V., & Tsezou, A. (2014) · Cellular Oncology · doi:10.1007/s13402-014-0213-5 · Cited by 28
Suzuki, Y., Ito, S., Sasaki, R., Asahi, M., & Ishida, Y. (2013) · Leukemia Research · doi:10.1016/j.leukres.2013.09.010 · Cited by 28
STAT3 and MCL-1 associate to cause a mesenchymal epithelial transition
Padmanabhan, R. A., Titus, S., Narayan, P., Murali, M., Jha, R. K., & Laloraya, M. (2014) · Journal of Cell Science · doi:10.1242/jcs.138214 · Cited by 29
San, T. T., Khaenam, P., Prachayasittikul, V., Sripa, B., Kunkeaw, N., & Chan-on, W. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e03255 · Cited by 30
Li, W., Huang, H., Su, J., Ji, X., Zhang, X., Zhang, Z., & Wang, H. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-9852-z · Cited by 26
RetractedKandala (2012) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2012.v6.2.94 · Cited by 27
“Phosphorylated STATs dimerize and translocate to nucleus, where they bind to specific regulatory sequences to activate or repress transcription of target genes such as Mcl-1 and survivin (12,13).”
BackgroundTotal Synthesis and Biological Activity of the Proposed Structure of Phaeosphaeride A
Chatzimpaloglou, A., Yavropoulou, M. P., de Rooij, K. E., Biedermann, R., Müeller, U., Kaskel, S., & Sarli, V. (2012) · The Journal of Organic Chemistry · doi:10.1021/jo301662e · Cited by 26
Artesunate induces apoptosis via inhibition of STAT3 in THP-1 cells
Tan, M., Rong, Y., Su, Q., & Chen, Y. (2017) · Leukemia Research · doi:10.1016/j.leukres.2017.09.022 · Cited by 28
Gattazzo, C., Teramo, A., Passeri, F., March, E. D., Carraro, S., Trimarco, V., Frezzato, F., Berno, T., Barilà, G., Martini, V., et al. (2014) · Haematologica · doi:10.3324/haematol.2014.105726 · Cited by 26
“Mean % (1)CD16/CD56 on lymphocytes (range) 34 (1-87)”
InfluentialBarilà, G., Grassi, A., Cheon, H., Teramo, A., Calabretto, G., Chahal, J., Vicenzetto, C., Almeida, J., Shemo, B. C., Shi, M., et al. (2022) · Blood · doi:10.1182/blood.2021013489 · Cited by 25
Self-citationCytokine-induced tumor suppressors: A GRIM story
Kalvakolanu, D. V., Nallar, S. C., & Kalakonda, S. (2010) · Cytokine · doi:10.1016/j.cyto.2010.03.009 · Cited by 25
“In general, the intrinsic and extrinsic pathways culminate in the activation of caspase-activated DNAse (CAD) [26] and generation of pro- apoptotic peptides from Bcl-2 and Bcl-XL proteins [27,28].”
InfluentialLewis, H. D., Winter, A., Murphy, T. F., Tripathi, S., Pandey, V. N., & Barton, B. E. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0154 · Cited by 25
Tanaka, K., Tanaka, T., Nakano, T., Hozumi, Y., Yanagida, M., Araki, Y., Iwazaki, K., Takagi, M., & Goto, K. (2019) · Cellular Signalling · doi:10.1016/j.cellsig.2019.109428 · Cited by 26
Large Granular Lymphocytic Leukemia: From Immunopathogenesis to Treatment of Refractory Disease
Zawit, M., Bahaj, W., Gurnari, C., & Maciejewski, J. P. (2021) · Cancers · doi:10.3390/cancers13174418 · Cited by 25
Genetic Interactions of STAT3 and Anticancer Drug Development
Fang, B. (2014) · Cancers · doi:10.3390/cancers6010494 · Cited by 27
“microRNA let-7 [148–151], and both of them regulate the common downstream targets, such as cyclin D1 [152–154], Bcl2 family proteins [155–158], Rho family GTPases [159–161], hypoxia-inducible factor-1α [162,163], and VEGF [9,164], suggesting that Ras and STAT3 mediate certain parallel,”
BackgroundCritical analysis of the potential for targeting STAT3 in human malignancy
Grandis, J., & Peyser (2013) · OncoTargets and Therapy · doi:10.2147/ott.s47903 · Cited by 24
“Other inhibition strategies include the introduction of antisense oligonucleotides, as in the case of the Isis Pharmaceuticals, Inc/AstraZeneca drug in clinical development, designed to cause degradation of STAT3 mRNA or prevent its translation via complementary base pairing, thereby reducing total STAT3 protein level…”
NAP1L1 regulates NF-κB signaling pathway acting on anti-apoptotic Mcl-1 gene expression
Tanaka, T., Hozumi, Y., Iino, M., & Goto, K. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2017.06.021 · Cited by 24
Galaxy tools to study genome diversity
Bedoya-Reina, O. C., Ratan, A., Burhans, R. C., Kim, H. L., Giardine, B. M., Riemer, C., Li, Q., Olson, T. L., Loughran, T. P., vonHoldt, B. M., et al. (2013) · GigaScience · doi:10.1186/2047-217x-2-17 · Cited by 25
“Previous reports [53] demonstrate constitutive STAT3 activation in all LGL leukemia samples, though one study [51] reported direct STAT3 mutations in only 31 of 77 patients.”
BackgroundSelf-citationT-large granular lymphocytic leukemia
Park, S. H., Lee, Y. J., Kim, Y., Kim, H., Lim, J., & Jo, J. (2023) · Blood Research · doi:10.5045/br.2023.2023037 · Cited by 24
“In pathobiology, abnormal activation of the JAK/STAT pathway promotes survival and sustains the abnormal persistence of clones that lack effector functions [14].”
BackgroundYu, L. J., Wang, B., Parobchak, N., Roche, N., & Rosen, T. (2015) · Placenta · doi:10.1016/j.placenta.2015.02.013 · Cited by 28
STAT3 Inhibitors in Cancer: A Comprehensive Update
Bharadwaj, U., Kasembeli, M. M., & Tweardy, D. J. (2016) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-42949-6_5 · Cited by 26
Lou, C., Chen, Y., Zhang, J., Yang, B., & Zhao, H. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01071 · Cited by 24
“Disruption of STAT3 signaling pathways leads to the inhibition of Bcl-xl, Mcl-1, and Bcl-2 (CatlettFalcone et al., 1999; Epling-Burnette et al., 2001; Bhattacharya et al., 2005) and activates the expression of the proapoptotic protein Bax 10 September 2019 | Volume 10 | Article 1071Frontiers in…”
BackgroundRetractedAnaplastic lymphoma kinase and its signalling molecules as novel targets in lymphoma therapy
Coluccia, A. M. L., Gunby, R. H., Tartari, C. J., Scapozza, L., Gambacorti-Passerini, C. B., & Passoni, L. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.3.515 · Cited by 26
“Intracellular delivery of ‘decoy’ oligonucleotides, carrying the consensus STAT-binding elements has been shown to downmodulate STAT3-activated gene expression in B cell lymphoma cells with a corresponding decrease in their proliferative potential [166,167].”
BackgroundIdentification of novel regulators of STAT3 activity
Parri, E., Kuusanmäki, H. A., van Adrichem, A. J., Kaustio, M., & Wennerberg, K. (2020) · PLoS ONE · doi:10.1371/journal.pone.0230819 · Cited by 25
“The observed cytostatic effects are in agreement with previous studies showing that STAT3 can protect cancer cells from the apoptotic effects of many individual drugs: STAT3 activity controls the expression of pro-survival genes such as MCL1, BCL2 and BCL2L1 [28, 29].”
ResultYang, W. J., Feng, Q., Li, M., Su, J., Wang, P., Wang, X., Yin, Y., Wang, X., & Zhao, M. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.684262 · Cited by 23
“Moreover, STAT3 signaling pathway positively regulates CyclinD1, Survivin, Bcl-2, Bcl-XL, and Mcl-1 to facilitate cancer cell cycle progression (Epling-Burnette et al., 2001; Lin et al., 2011).”
BackgroundClassical cadherins control survival through the gp130/Stat3 axis
Geletu, M., Arulanandam, R., Chevalier, S. A., Sáez, B., Larue, L., Feracci, H., & Raptis, L. H. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2013.03.014 · Cited by 28
Nagy, Z. S., Rui, H., Stepkowski, S. M., Karras, J. G., & Kirken, R. A. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.8.5032 · Cited by 25
“The mechanism underlying cell survival supported by STAT3 has been linked to the transcriptional control of apoptotic regulatory genes, such as bcl-xL, bax (48), and mcl-1 (17), as well as cell cycle regulator p21 (58).”
BackgroundSelf-citationPontikoglou, C. G., Kalpadakis, C. H., & Papadaki, H. Α. (2011) · Expert Review of Hematology · doi:10.1586/ehm.11.26 · Cited by 23
Paeoniflorin inhibits the growth of bladder carcinoma via deactivation of STAT3
Yang, J., Ren, Y., Lou, Z., Wan, X., Weng, G., & Cen, D. (2018) · Acta Pharmaceutica · doi:10.2478/acph-2018-0013 · Cited by 27
Preclinical Studies of Novel Targeted Therapies
Hideshima, T., & Anderson, K. C. (2007) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2007.08.013 · Cited by 28
Wagner, V., Hose, D., Seckinger, A., Weiz, L., Meißner, T., Rème, T., Breitkreutz, I., Podar, K., Ho, A. D., Goldschmidt, H., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2529 · Cited by 25
“How does YM155 suppress expression of survivin and Mcl-1? Firstly, both Mcl-1 and survivin expression have been found to be regulated by STAT3 [33, 46, 47].”
Assmann, J. L. J. C., León, L. G., Stavast, C. J., van den Bogaerdt, S. E., Schilperoord‐Vermeulen, J., Sandberg, Y., Bellido, M., Erkeland, S. J., Feith, D. J., Loughran, T. P., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01480-2 · Cited by 24
“Specific inhibition of STAT3 with antisense oligos or through JAK inhibition with AG-490 in T-LGL leukemic cells restores their ability to go into apoptosis in vitro [3], clearly showcasing the importance of STAT3 in T-LGL survival.”
BackgroundSelf-citationStat3 is involved in the motility, metastasis and prognosis in lingual squamous cell carcinoma
Zhao, Y., Zhang, J., Xia, H., Zhang, B., Jiang, T., Wang, J., Chen, X., & Wang, Y. (2012) · Cell Biochemistry and Function · doi:10.1002/cbf.2810 · Cited by 25
Self-citationKian, M. M., Salemi, M., Bahadoran, M., Haghi, A., Dashti, N., Mohammadi, S., Rostami, S., Chahardouli, B., Babakhani, D., & Nikbakht, M. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s228610 · Cited by 23
“Inhibition of STAT3 signaling cascades causes cell apoptosis and ultimately leukemia remission.(14,15) BCL-XL is a member of BCL-2 families.”
BackgroundNever Say Die: Survival Signaling in Large Granular Lymphocyte Leukemia
Shah, M. V., Zhang, R., & Loughran, T. P. (2009) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2009.s.019 · Cited by 24
Self-citationShao, H., Xu, X., Jing, N., & Tweardy, D. J. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.5.2933 · Cited by 24
“Targeting of Stat3 using antisense strategies, dominant-negative constructs, and oligonucleotides that destabilize Stat3 dimers have been shown experimentally to induce apoptosis and reduce tumor cell growth in a variety of human cancers, including large granular lymphocytic leukemia (53), myeloma (54), breast (55, 56…”
BackgroundEffects of the Tumor Microenvironment on the Efficacy of Tumor Immunotherapy
Neeson, P. J., & Paterson, Y. Y. W. (2006) · Immunological Investigations · doi:10.1080/08820130600755009 · Cited by 24
High expression of Mcl-1 in ALK positive and negative anaplastic large cell lymphoma
Rust, R., Harms, G., Blokzijl, T., Boot, M., Diepstra, A., Kluiver, J. L., Visser, L., Peh, S., Lim, M. S., Kamps, W. A., et al. (2005) · Journal of Clinical Pathology · doi:10.1136/jcp.2004.022335 · Cited by 22
“This is supported by two studies that show the involvement of the phosphatidylinositol 3kinase pathway in the upregulation of Mcl-1 expression.(33,35)”
ResultAll that glitters is not LGL Leukemia
Semenzato, G., Teramo, A., Calabretto, G., Gasparini, V. R., & Zambello, R. (2022) · Leukemia · doi:10.1038/s41375-022-01695-x · Cited by 24
“STAT signaling is paramount to direct the cell toward survival, being STAT an inducer of the transcription of many pro-survival genes [71, 72].”
BackgroundExtrinsic and intrinsic drivers of natural killer cell clonality
Rückert, T., & Romagnani, C. (2024) · Immunological Reviews · doi:10.1111/imr.13324 · Cited by 22
“237 Sustained expression of the pro-survival factor MCL1 prevents cell death, for example, in response to FAS engagement 238 or after activation.”
BackgroundHippuristanol Reduces the Viability of Primary Effusion Lymphoma Cells both in Vitro and in Vivo
Ishikawa, C., Tanaka, J., Katano, H., Senba, M., & Mori, N. (2013) · Marine Drugs · doi:10.3390/md11093410 · Cited by 21
“A link between STAT3 activation and regulation of Bcl-2 family protein expression has been demonstrated [22].”
BackgroundGeletu, M., Mohan, R., Arulanandam, R., Berger‐Becvar, A., Nabi, I. R., Gunning, P. T., & Raptis, L. H. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2018.02.004 · Cited by 21
Metadata
- Authors
- Epling-Burnette, P. K., Liu, J. H., Catlett-Falcone, R., Turkson, J., Oshiro, M., Kothapalli, R., Li, Y., Wang, J.-M., Yang-Yen, H.-F., Karras, J., Jove, R., & Loughran, T. P.
- Affiliations
- University of South Florida (US)
- National Taiwan University (TW)
- Ionis Pharmaceuticals (United States) (US)
- Venue
- Journal of Clinical Investigation
- Published
- 2001-02-01
- Volume
- 107
- Issue
- 3
- Pages
- 351-362
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC199188
- OpenAlex
- W2041204531
- Cited by
- 633
- References
- 60
- Citations by year
- 2026: 7 · 2025: 12 · 2024: 14 · 2023: 20 · 2022: 25 · 2021: 26 · 2020: 31 · 2019: 22 · 2018: 14 · 2017: 27 · 2016: 15 · 2015: 27 · 2014: 46 · 2013: 31 · 2012: 35
- FWCI
- 12.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Cancer Society
- Moffitt Cancer Center
- National Institutes of Health (5r21ca078724-02)
- National Cancer Institute (R01CA055652, CA-55652, CA78724)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- large granular lymphocyte leukemia, STAT3 signaling, apoptosis, Mcl-1, Fas resistance, AG490, antisense oligonucleotides, Bcl-2 family proteins, v-Src
- MeSH terms
- Cell Line, DNA-Binding Proteins, Enzyme Inhibitors, Gene Expression Regulation, Humans, Leukemia, Neoplasm Proteins, Phosphorylation, Tumor Cells, Cultured, Blotting, Western, Signal Transduction, Trans-Activators, Oncogene Protein pp60(v-src), Apoptosis, CD8-Positive T-Lymphocytes, Proto-Oncogene Proteins c-bcl-2, Dimerization, Tyrphostins, STAT3 Transcription Factor, Myeloid Cell Leukemia Sequence 1 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.